Rituximab ITP Aiha denied for failing step therapy by Humana?

Humana's specific coverage criteria for rituximab itp aiha are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Requires Step Therapy Before Rituximab for ITP / AIHA — and Why You Can Appeal

Step-therapy (also called "fail-first") denials mean Humana's policy requires documented failure of one or more preferred treatments before it will authorize rituximab for immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA). These denials are common even when a patient has already tried and failed multiple agents, simply because the prior failures are not adequately documented in the submitted request.

## Why This Denial Is Appealable

Step-therapy protocols must have a clinical basis and are required to include exemptions when preferred therapies have already failed, are contraindicated, or are otherwise clinically inappropriate for the individual patient. If your records show prior treatment attempts that were not recognized in the initial review — or if your prescriber documents a clinical reason why the required steps are unsafe or futile for your specific case — the denial is highly contestable. Many states also have step-therapy override laws that impose additional protections beyond federal minimums.

## Federal Appeal Framework

• Internal appeal — ERISA §503 (employer plans) or applicable state law requires a full-and-fair review of your individualized clinical circumstances. File within the deadline on your Explanation of Benefits.
• External review — ACA §2719 gives you the right to an independent external review after an adverse internal determination, generally within approximately four months of the final denial.
• Expedited review — Available when your clinical situation is urgent or ongoing treatment is at risk of interruption.

## Concrete Appeal Steps and Timeline

1. Obtain Humana's written rituximab step-therapy policy; confirm exactly which agents must be tried and in what sequence. 2. File a written internal appeal, citing each required step and the chart documentation of your response (or inability to use) each agent. 3. If the internal appeal is denied, file for external review within the timeframe stated on the final adverse determination notice. 4. Request expedited external review if your clinical condition is urgent.

## Documentation to Gather

• Diagnosis records — confirmed ITP or AIHA diagnosis with dates and lab trends.
• Prior treatment history — for every required step-therapy agent: start date, end date, dose adjustments attempted, objective response data, and reason for discontinuation (failure, intolerance, adverse event).
• Clinical severity documentation — transfusion requirements, bleeding events, hemolytic episodes, and current lab values from the chart.
• Prescriber medical-necessity letter — explaining why prior steps were inadequate and why rituximab is now the appropriate next intervention according to recognized hematology society guidance.
• Safety or contraindication documentation — if any required step agent is clinically inappropriate for this patient, chart notes and prescriber explanation supporting that position.

## Criteria-Mapping Structure

Obtain the exact step-therapy requirements from Humana's published policy. Map each one to your chart:

| Step-Therapy Requirement | Chart Evidence | |---|---| | Step 1 agent trialed | [Agent, start/end dates, outcome documented in records] | | Step 2 agent trialed (if required) | [Agent, start/end dates, outcome documented in records] | | Adequate duration of each step | [Date range, prescriber attestation of adequate trial] | | Clinical failure or intolerance documented | [Chart note, lab data, adverse event record] | | Rituximab appropriate per specialty guideline | [Prescriber letter referencing applicable hematology society guidance] |

Completeness is the key: every unfilled row is a reason for the reviewer to uphold the denial. Fill them all.